Amendments to the Claims

1. – 29. (canceled)

30. (new) A compound of formula (I) or a salt thereof:



(I)

wherein:

R^1 is ethyl, n-propyl, isopropyl, C_{1-2}fluoroalkyl, or $-CH_2CH_2OH$;

R^2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, C_{1-2}fluoroalkyl, cyclopropyl or (cyclopropyl)methyl-;

NHR^3 has the sub-formula (nhr3):



(nhr3)

wherein, in sub-formula (nhr3), the -NH- connection point of the NHR^3 group to the bicyclic ring system of formula (I) is underlined, and wherein

R^{3a} is methyl or ethyl;

R^{3b} is hydrogen, methyl or ethyl,

R^{3c} is hydrogen, methyl or ethyl,

R^{3d} is hydrogen, methyl or ethyl, and

R^{3e} is hydrogen or methyl,

provided that:

(a) R^{3b} is methyl or ethyl; and (b) R^{3c} and R^{3d} are independently methyl or ethyl;

and provided that:

(c) when R^{3c} is ethyl and when R^{3d} is ethyl and when R^{3e} is methyl, then: R^{3a} is methyl and R^{3b} is hydrogen or methyl;

and wherein:

R^5 is C_{3-8}alkyl; C_{3-8}cycloalkyl optionally substituted by a C_{1-2}alkyl group; or -$(CH_2)_n{}^4$-C_{3-8}cycloalkyl optionally substituted, in the -$(CH_2)_n{}^4$- moiety or in the C_{3-8}cycloalkyl moiety, by a C_{1-2}alkyl group, wherein n^4 is 1, 2 or 3;

or R^5 is C_{2-6}alkyl substituted by one or two independent substituents R^{11}; wherein each substituent R^{11}, independently of any other R^{11} substituent present, is: hydroxy; C_{1-6}alkoxy; phenyloxy; benzyloxy; -$NR^{12}R^{13}$; -NR^{15}-C(O)R^{16}; -NR^{15}-C(O)-NH-R^{15}; or -NR^{15}-SO_2R^{16}; and wherein any R^{11} substituent which is OH, alkoxy or -$NR^{12}R^{13}$ is not substituted at the carbon atom, of any R^5 substituted alkyl, which is bonded to the nitrogen of NHR^5;

or R^5 is -$(CH_2)_n{}^{12}$-SO_2-$NR^{12}R^{13}$ or -$(CH_2)_n{}^{12}$-SO_2R^{16}; wherein n^{12} is 2, 3 or 4;

or R^5 is -$(CH_2)_n{}^{13}$-Het wherein n^{13} is 0, 1, 2, 3 or 4 and Het is a 4-, 5-, 6- or 7-membered saturated or partly-saturated heterocyclic ring containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the -$(CH_2)_n{}^{13}$- moiety when n^{13} is 1 and are not bound to the nitrogen of NHR^5 when n^{13} is 0; wherein any ring-nitrogens which are present and which are saturated are present as NR^{17}; and wherein one or two of the carbon ring-atoms independently are optionally substituted by C_{1-2}alkyl;

or R^5 has the sub-formula (x), (xa), (y), (y1), (z) or (za):



(x)



(xa)



(y)



(y1)



(z)



(za)

wherein in sub-formula (x), n = 0, 1 or 2; in sub-formula (y) and (y1), m = 1 or 2; and in sub-formula (z), r = 0, 1 or 2;

wherein sub-formula (y) and (y1), independently, are optionally substituted by oxo at a ring carbon adjacent the 6-membered aromatic ring;

and wherein, in sub-formula (xa) and (za):

R^{4a} is hydrogen; methyl, ethyl, n-propyl, isopropyl, C_{1-2}fluoroalkyl, cyclopropyl, $-CH_2OR^{4aa}$, $-CH(Me)OR^{4aa}$, or $-CH_2CH_2OR^{4aa}$, wherein R^{4aa} is hydrogen, methyl, or C_1fluoroalkyl; and

R^{5a} is-hydrogen; C_{1-8}alkyl; C_{1-3}fluoroalkyl; C_{3-8}cycloalkyl optionally substituted by a C_{1-2}alkyl group; or $-(CH_2)_n{}^{4a}$-C_{3-8}cycloalkyl optionally substituted, in the $-(CH_2)_n{}^{4a}$- moiety or in the C_{3-8}cycloalkyl moiety, by a C_{1-2}alkyl group, wherein n^{4a} is 1 or 2;

or R^{5a} is C_{1-4}alkyl substituted by one substituent R^{11a}; wherein R^{11a} is: hydroxy (OH); C_{1-6}alkoxy; C_{1-2}fluoroalkoxy; phenyloxy; (monofluoro- or difluoro-phenyl)oxy; (monomethyl- or dimethyl-phenyl)oxy; benzyloxy; $-NR^{12}R^{13}$; $-NR^{15}$-$C(O)R^{16}$; $-NR^{15}$-C(O)-NH-R^{15}; or $-NR^{15}$-$S(O)_2R^{16}$;

or R^{5a} is C_{2-4}alkyl substituted on different carbon atoms by two hydroxy substituents;

or R^{5a} is $-(CH_2)_n{}^{11a}$-$C(O)R^{16}$; $-(CH_2)_n{}^{11a}$-$C(O)NR^{12}R^{13}$; $-CHR^{19a}$-$C(O)NR^{12}R^{13}$; $-(CH_2)_n{}^{11a}$-$C(O)OR^{16}$; $-(CH_2)_n{}^{11a}$-C(O)OH; $-CHR^{19a}$-$C(O)OR^{16}$; $-CHR^{19a}$-C(O)OH; $-(CH_2)_n{}^{11a}$-$S(O)_2$-$NR^{12}R^{13}$;

$-(CH_2)_n{}^{11a}-S(O)_2R^{16}$; or $-(CH_2)_n{}^{11a}-CN$; wherein n^{11a} is 0, 1, 2 or 3 wherein for each R^{5a} group n^{11a} is independent of the value of n^{11a} in other R^{5a} groups; and wherein R^{19a} is C_{1-2}alkyl;

or R^{5a} is $-(CH_2)_n{}^{13a}-Het^A$, wherein n^{13a} is 0, 1 or 2 and Het^A is a 4-, 5-, 6- or 7-membered saturated or unsaturated heterocyclic ring, other than $-NR^{12}R^{13}$, containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the $-(CH_2)_n{}^{13a}$ moiety when n^{13a} is 0; wherein any ring-nitrogens which are present and which are saturated and which are not connecting nitrogens are present as NR^{17a}; and wherein one or two of the carbon ring-atoms are independently optionally substituted by C_{1-2}alkyl;

or R^{5a} is phenyl, $-CH_2$-Ph, -CHMe-Ph, -CHEt-Ph, CMe_2Ph, or $-CH_2CH_2$-Ph, wherein the phenyl ring is optionally substituted with one or two substituents independently selected from the group consisting of a halogen atom; C_{1-4}alkyl; C_{1-2}fluoroalkyl; C_{1-4}alkoxy; C_{1-2}fluoroalkoxy; cyclopropyl; cyclopropyloxy; $-C(O)-C_{1-4}$alkyl; -C(O)OH; $-C(O)-OC_{1-4}$alkyl; C_{1-4}alkyl-$S(O)_2$-; C_{1-4}alkyl-$S(O)_2-NR^{8a}$-; $R^{7a}R^{8a}N-S(O)_2$-; $R^{7a}R^{8a}N-C(O)$-; $-NR^{8a}-C(O)-C_{1-4}$alkyl; $R^{7a}R^{8a}N$; OH; nitro ($-NO_2$); and cyano (-CN);

or R^{4a} and R^{5a} taken together are $-(CH_2)_p{}^1-$ or $-(CH_2)_p{}^3-X^5-(CH_2)_p{}^4$-, in which: X^5 is O or NR^{17a}; p^1 = 2, 3, 4, 5 or 6, and p^3 and p^4 independently are 1, 2 or 3 provided that if p^3 is 3 then p^4 is 1 or 2 and if p^4 is 3 then p^3 is 1 or 2;

provided that at least one of R^{4a} and R^{5a} is not hydrogen;

and wherein, in sub-formula (x) and in sub-formula (xa):

A is C-R^{6A}, nitrogen or nitrogen-oxide,

B is C-R^{6B}, nitrogen or nitrogen-oxide,

D is C-R^{6D}, nitrogen or nitrogen-oxide,

E is C-R^{6E}, nitrogen or nitrogen-oxide,

F is C-R^{6F}, nitrogen or nitrogen-oxide,

wherein, R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F} independently are: hydrogen, a halogen atom; C_{1-6}alkyl; C_{1-4}fluoroalkyl; C_{3-6}cycloalkyl; C_{1-4}alkoxy; C_{1-2}fluoroalkoxy; C_{3-6}cycloalkyloxy; $-C(O)R^{16a}$; $-C(O)OR^{30}$; $-S(O)_2-R^{16a}$; $R^{16a}-S(O)_2-NR^{15a}$-; $R^7R^8N-S(O)_2$-; C_{1-2}alkyl-$C(O)-R^{15a}N-S(O)_2$-; C_{1-4}alkyl-S(O)-, Ph-S(O)-, R^7R^8N-CO-; $-NR^{15a}-C(O)R^{16a}$; R^7R^8N; nitro; OH; C_{1-4}alkoxymethyl; C_{1-4}alkoxyethyl; C_{1-2}alkyl-$S(O)_2-CH_2$-; $R^7R^8N-S(O)_2-CH_2$-;

C_{1-2}alkyl-S(O)$_2$-NR^{15a}-CH_2-; -CH_2-OH; -CH_2CH_2-OH; -CH_2-NR^7R^8; -CH_2-CH_2-NR^7R^8; -CH_2-C(O)OR^{30}; -CH_2-C(O)-NR^7R^8; -CH_2-NR^{15a}-C(O)-C_{1-3}alkyl; -$(CH_2)_n{}^{14}$-Het^1 where n^{14} is 0 or 1; cyano; Ar^{5b}; or phenyl, pyridinyl or pyrimidinyl wherein the phenyl, pyridinyl or pyrimidinyl independently are optionally substituted by one or two substituents selected from the group consisting of fluoro, chloro, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy;

and two adjacent groups are selected from the group consisting of R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F}, and are: –CH=CH–CH=CH_2–, –$(CH_2)_n{}^{14a}$– where n^{14a} is 3, 4 or 5, –O–(CMe_2)–O–, –O–$(CH_2)_n{}^{14b}$–O– where n^{14b} is 1 or 2; -CH=CH-NR^{15b}-; -N=CH-NR^{15b}-; -CH=N-NR^{15b}-; -N=N-NR^{15b}-; -CH=CH-O-; -N=CH-O-; -CH=CH-S-; or -N=CH-S-; wherein R^{15b} is H or C_{1-2}alkyl;

provided that:

at least two of A, B, D, E and F are independently C-H, C-F, nitrogen, or nitrogen-oxide;

and no more than two of A, B, D, E and F are independently nitrogen or nitrogen-oxide,

and no more than one of A, B, D, E and F is nitrogen-oxide;

and wherein, in sub-formula (z) and in sub-formula (za):

G is O or S or NR^9 wherein R^9 is hydrogen, C_{1-4}alkyl, or C_{1-2}fluoroalkyl;

J is C-R^{6J}, C-[connection point to formula (I)], or nitrogen,

L is C-R^{6L}, C-[connection point to formula (I)], or nitrogen,

M is C-R^{6M}, C-[connection point to formula (I)], or nitrogen,

Q is C-R^{6Q}, C-[connection point to formula (I)], or nitrogen,

wherein, R^{6J}, R^{6L}, R^{6M} and R^{6Q} independently are:-hydrogen, a halogen atom; C_{1-4}alkyl; C_{1-3}fluoroalkyl; C_{3-6}cycloalkyl; C_{1-4}alkoxy; C_{1-2}fluoroalkoxy; C_{3-6}cycloalkyloxy; OH (including any tautomer thereof); or phenyl optionally substituted by one or two substituents independently selected from the group consisting of fluoro, chloro, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy;

provided that:

at least two of J, L, M and Q are independently C-H, C-F, C-C_{1-2}alkyl, C-[connection point to formula (I)], or nitrogen;

and no more than three of J, L, M and Q are nitrogen;

and wherein:

R^7 and R^8 are independently hydrogen; C_{1-4}alkyl; C_{3-6}cycloalkyl; or phenyl optionally substituted by one or two substituents independently selected from the group consisting of: fluoro, chloro, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy;

or R^7 and R^8 together are $-(CH_2)_n{}^6-$ or $-C(O)-(CH_2)_n{}^7-$ or $-C(O)-(CH_2)_n{}^{10}-C(O)-$ or $-(CH_2)_n{}^8-X^7-(CH_2)_n{}^9-$ or $-C(O)-X^7-(CH_2)_n{}^{10}$ in which: n^6 is 3, 4, 5 or 6, n^7 is 2, 3, 4, or 5, n^8 and n^9 and n^{10} independently are 2 or 3, and X^7 is O or NR^{14};

R^{7a} is hydrogen or C_{1-4}alkyl;

R^{8a} is hydrogen or methyl;

R^{12} and R^{13}, independent of any other R^{12} or R^{13} independently are H; C_{1-4}alkyl; C_{3-6}cycloalkyl; or phenyl optionally substituted by one or two substituents independently selected from the group consisting of fluoro, chloro, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy;

or R^{12} and R^{13}, independent of any other R^{12} or R^{13}, together are $-(CH_2)_n{}^{6a}-$ or $-C(O)-(CH_2)_n{}^{7a}-$ or $-C(O)-(CH_2)_n{}^{10a}-C(O)-$ or $-(CH_2)_n{}^{8a}-X^{12}-(CH_2)_n{}^{9a}-$ or $-C(O)-X^{12}-(CH_2)_n{}^{10a}-$ in which: n^{6a} is 3, 4, 5 or 6, n^{7a} is 2, 3, 4, or 5, n^{8a} and n^{9a} and n^{10a} independently are 2 or 3 and X^{12} is O or NR^{14a};

R^{14}, R^{14a} and R^{17a}, independent of any other R^{14}, R^{14a} or R^{17a}, independently are: hydrogen; C_{1-4}alkyl; C_{1-2}fluoroalkyl; cyclopropyl; $-C(O)-C_{1-4}$alkyl; $-C(O)NR^{7a}R^{8a}$; or $-S(O)_2-C_{1-4}$alkyl;

R^{15}, independent of any other R^{15}, is hydrogen; C_{1-4}alkyl; C_{3-6}cycloalkyl; or phenyl optionally substituted by one or two substituents independently selected from the group consisting of: a halogen atom, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy;

R^{15a}, independent of any other R^{15a}, is hydrogen or C_{1-4}alkyl;

R^{16}, independent of any other R^{16}, is: C_{1-4}alkyl; C_{3-6}cycloalkyl; C_{3-6}cycloalkyl-CH_2-; or phenyl or benzyl, wherein the phenyl and benzyl are independently optionally substituted by one or two substituents independently

selected from the group consisting of fluoro, chloro, methyl, C_1fluoroalkyl, methoxy and C_1fluoroalkoxy;

R^{16a}, independent of any other R^{16a}, is: C_{1-6}alkyl; C_{3-6}cycloalkyl optionally substituted by one oxo, OH or C_{1-2}alkyl substituent; C_{3-6}cycloalkyl-CH_2-; pyridinyl optionally substituted on a ring carbon atom by one of: a halogen atom, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy or C_1fluoroalkoxy; Ar^{5c}; phenyl optionally substituted by one or two substituents independently selected from the group consisting of: a halogen atom, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy; benzyl optionally substituted on its ring by one or two substituents independently selected from the group consisting of: a halogen atom, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy, C_1fluoroalkoxy; or a 4-, 5-, 6- or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from the group consisting of O, S, and N; wherein any ring-nitrogens which are present are present as NR^{27} where R^{27} is H, C_{1-2}alkyl or -C(O)Me; and wherein the ring is optionally substituted at carbon by one C_{1-2}alkyl or oxo substituent, provided that any oxo substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen;

R^{17}, independent of any other R^{17}, is hydrogen; C_{1-4}alkyl; C_{1-2}fluoroalkyl; C_{3-6}cycloalkyl; $-(CH_2)_p{}^6$-C(O)R^{16} wherein p^6 is 0, 1, 2 or 3; $-(CH_2)_p{}^6$-C(O)$NR^{12}R^{13}$; $-(CH_2)_p{}^6$-C(O)OR^{16}; $-(CH_2)_p{}^6$-C(O)OH; $-SO_2R^{16}$; -C(O)-CH_2-$NR^{12}R^{13}$; -C(O)-CH_2-NR^{15a}-C(O)-C_{1-3}alkyl; -C(O)-CH_2-O-C_{1-3}alkyl; or phenyl or benzyl wherein the phenyl or benzyl is optionally substituted on their ring by one or two substituents independently selected from the group consisting of: a halogen atom, C_{1-2}alkyl, C_1fluoroalkyl, C_{1-2}alkoxy and C_1fluoroalkoxy;

R^{30}, independent of any other R^{30}, is hydrogen, C_{1-4}alkyl or C_{3-6}cycloalkyl;

Ar^{5b} and Ar^{5c} independently are a 5-membered aromatic heterocyclic ring containing one O, S or NR^{15a}, the ring can optionally additionally contain one or two N atoms, and wherein the heterocyclic ring is optionally substituted on a ring carbon atom by a substituent selected from the group consisting of: halo, C_{1-2}alkyl, C_1fluoroalkyl, -CH_2OH, -CH_2-OC_{1-2}alkyl, OH, and –CH_2-$NR^{28}R^{29}$ wherein R^{28} and R^{29} independently are H or methyl; and

Het^1, independent of any other Het^1, is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from the group consisting of O, S, and N; wherein any ring-nitrogens which are present are present as NR^{31} where R^{31} is H, C_{1-2}alkyl or -C(O)Me; and wherein the ring is optionally substituted at carbon by one C_{1-2}alkyl or oxo substituent, provided that any oxo substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen.

31. (new) A compound or salt as claimed in claim 30, wherein R^1 is ethyl or C_2fluoroalkyl.

32. (new) A compound or salt as claimed in claim 30, wherein R^1 is ethyl.

33. (new) A compound or salt as claimed in claim 30 wherein R^2 is hydrogen or methyl.

34. (new) A compound or salt as claimed in claim 30 wherein R^{3a} is methyl, R^{3b} is hydrogen or methyl, and R^{3e} is hydrogen.

35. (new) A compound or salt as claimed in claim 30 wherein R^{3b} is methyl or ethyl, R^{3c} and R^{3d} independently are-hydrogen or methyl, and R^{3e} is-hydrogen.

36. (new) A compound or salt as claimed in claim 35, wherein R^3 is t-butyl.

37. (new) A compound or salt as claimed in claim 30 wherein R^{3c} and R^{3d} are independently methyl or ethyl, R^{3a} is methyl, and R^{3b} is hydrogen or methyl.

38. (new) A compound or salt as claimed in claim 37, wherein R^3 is 1,2-dimethyl-propyl.

39. (new) A compound or salt as claimed in claim 30 wherein R^{3c} and R^{3d} are independently methyl or ethyl, R^{3b} is hydrogen and NHR^3 has the sub-formula (nhr3a):



(nhr3a) ,

wherein sub-formula (nhr3a) means that more than 50% of the compound or salt present has the stereochemistry shown at the carbon atom bearing the R^{3a} and R^{3b} groups.

40. (new) A compound or salt as claimed in claim 39 wherein NHR^3 has the sub-formula: 

.

41. (new) A compound or salt as claimed in claim 30 wherein R^5 is C_{3-8}alkyl; C_{5-6}cycloalkyl; (C_{5-6}cycloalkyl)methyl-; $-(CH_2)_{n^5}-R^{11}$ wherein n^5 is 2 or 3 or R^{11} is $-NR^{15}-SO_2R^{16}$; or R^5 has the sub-formula (x), (xa), (y), (y1), (z) or (za).

42. (new) A compound or salt as claimed in claim 41 wherein R^5 has the sub-formula (x), (xa), (y), (y1), (z) or (za).

43. (new) A compound or salt as claimed in claim 42 wherein R^5 has the sub-formula (x), (xa), (y), or (z).

44. (new) A compound or salt as claimed in claim 43 wherein R^5 has the sub-formula (x) or (xa).

45. (new) A compound or salt as claimed in claim 30 wherein n = 1, m = 1 and r = 1.

46. (new) A compound or salt as claimed in claim 44 wherein:

R^5 is sub-formula (x) which is $-(CH_2)_n-Ar^X$, or sub-formula (xa) which is $-(CR^{4a}R^{5a})-Ar^X$,

and Ar^X is sub-formula (x1), (x2), (x3), (x4), (x5), (x6), (x7), (x8), (x9), (x10), (x11), (x12), (x13), (x14), (x15) or (x16):



(x1)



(x2)



(x3)



(x4)



(x5)



(x6)



(x7)



(x8)



(x9)



(x10)



(x11)



(x12)



(x13)



(x14)



(x15)



(x16)

47. (new) A compound or salt as claimed in claim 46 wherein Ar^X has the sub-formula (x1).

48. (new) A compound or salt as claimed in claim 30 wherein, in sub-formula (x) and in sub-formula (xa), R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F}, independently of each other, are hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, $-CH_2OH$, methoxy, ethoxy, n-propoxy, isopropoxy,

C_1fluoroalkoxy, nitro (-NO_2), OH, C_{1-3}alkylS(O)$_2$-, C_{1-2}alkylS(O)$_2$-NH-, -$CONH_2$, cyano (-CN), or C_{1-2}alkylS(O)$_2$-CH_2-.

49. (new) A compound or salt as claimed in claim 48 wherein R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F}, independently of each other, are: hydrogen, fluoro, chloro, bromo, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, -CH_2OH, methoxy, ethoxy, n-propoxy, difluoromethoxy, nitro (-NO_2), OH, MeS(O)$_2$-, Me-S(O)$_2$-NH- or Me-S(O)$_2$-CH_2-.

50. (new) A compound or salt as claimed in claim 30 wherein R^5 is: benzyl, (monoalkyl-phenyl)methyl, [mono(fluoroalkyl)-phenyl]methyl, (monohalo-phenyl)methyl, (monoalkoxy-phenyl)methyl, [mono(fluoroalkoxy)-phenyl]methyl, [mono(N,N-dimethylamino)-phenyl]methyl, [mono(methyl-SO_2-NH-)-phenyl]methyl, [mono(methyl-SO_2-)-phenyl]methyl, (dialkyl-phenyl)methyl, (monoalkyl-monohalo-phenyl)methyl, [mono(fluoroalkyl)-monohalo-phenyl]methyl, (dihalo-phenyl)methyl, (dihalo-monoalkyl-phenyl)methyl, [dihalo-mono(hydroxymethyl)-phenyl]methyl, or (dialkoxy-phenyl)methyl.

51. (new) A compound or salt as claimed in claim 50 wherein R^5 is:
(monoC_{1-4}alkyl-phenyl)methyl;
(monoC_1fluoroalkyl-phenyl)methyl;
(monoC_{1-3}alkoxy-phenyl)methyl;
[mono(C_1fluoroalkoxy)-phenyl]methyl;
(diC_{1-2}alkyl-phenyl)methyl;
(monoC_{1-4}alkyl-monohalo-phenyl)methyl;
(dihalo-phenyl)methyl;
(dihalo-monoC_{1-2}alkyl-phenyl)methyl; or
[dihalo-mono(hydroxymethyl)-phenyl]methyl.

52. (new) A compound or salt as claimed in claim 30 which is:
N-benzyl-4-{[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2,3-dihydro-1H-inden-2-yl)-4-{[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[4-(difluoromethoxy)benzyl]-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(2-methyl-1,3-thiazol-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[(5-chloropyridin-2-yl)methyl]-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2-chloro-6-fluorobenzyl)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-{1-[4-(methylsulfonyl)phenyl]ethyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(6-methoxypyridin-3-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-{3-[(methylamino)carbonyl]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-N-(2,2-diphenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[2-(dimethylamino)benzyl]-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-N-(diphenylmethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-{4-[(methylamino)carbonyl]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

methyl 4-({[(4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)carbonyl]amino}methyl)benzoate,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-methoxyphenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-hydroxybenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[3-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(3,4-difluorobenzyl)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2,6-difluorobenzyl)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2,5-difluorobenzyl)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(3-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[2-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

methyl 3-({[(4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)carbonyl]amino}methyl)benzoate,

N-[2-(aminocarbonyl)benzyl]-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-{4-[(methylsulfonyl)amino]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-{3-[(methylsulfonyl)amino]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2,3-dihydro-1H-inden-2-yl)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-benzyl-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[2-(aminosulfonyl)ethyl]-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(6-oxo-1,6-dihydropyridin-3-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-{2-[(methylsulfonyl)amino]ethyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[3-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(pyridin-3-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[3-(aminocarbonyl)benzyl]-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-{4-[(dimethylamino)sulfonyl]benzyl}-4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-{[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(2-ethylbutyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-1-ethyl-N-benzyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-1-ethyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, or

4-(tert-butylamino)-1-ethyl-N-[4-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide.

53. (new) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 30 and one or more pharmaceutically acceptable carriers and/or excipients.

54. (new) A method of treatment and/or prophylaxis of an inflammatory and/or allergic disease in a human in need thereof which method comprises administering to the human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 30.

55. (new) The method of claim 54 wherein the disease is chronic obstructive pulmonary disease or asthma.